SVVYGLR motif of the thrombin-cleaved N-terminal osteopontin fragment enhances the synthesis of collagen type III in myocardial fibrosis
- PMID: 26112906
- DOI: 10.1007/s11010-015-2495-y
SVVYGLR motif of the thrombin-cleaved N-terminal osteopontin fragment enhances the synthesis of collagen type III in myocardial fibrosis
Abstract
Osteopontin (OPN) is involved in various physiological processes such as inflammatory and wound healing. However, little is known about the effects of OPN on these tissues. OPN is cleaved by thrombin, and cleavage of the N-terminal fragment exposes a SVVYGLR sequence on its C-terminus. In this study, we examined the effects of the thrombin-cleaved OPN fragments on fibroblasts and myocardial fibrosis, particularly the role of the SVVYGLR sequence. The recombinant thrombin-cleaved OPN fragments (N-terminal fragment [N-OPN], C-terminal fragment [C-OPN], and the N-terminal fragment lacking the SVVYGLR sequence [ΔSV N-OPN]) were added to fibroblasts, and the cellular motility, signal activity, and production of collagen were evaluated. A sustained-release gel containing an OPN fragment or SVVYGLR peptide was transplanted into a rat model of ischemic cardiomyopathy and the quantities and ratio of collagen type I (COL I) and type III (COL III) were estimated. N-OPN significantly promoted fibroblast migration. Smad signal activity, expression of smooth muscle actin (SMA), and the production of COL III were enhanced by N-OPN and SVVYGLR peptide. Conversely, ΔSV N-OPN and C-OPN had no effect. In vivo, the expression level of N-OPN was associated with COL III distribution, and the COL III/COL I ratio was significantly increased by the sustained-release gel containing N-OPN or SVVYGLR peptide. The cardiac function was also significantly improved by the N-OPN- or SVVYGLR peptide-released gel treatment. The N-terminal fragment of thrombin-cleaved OPN-induced Smad signal activation, SMA expression, and COL III production, and its SVVYGLR sequence influences this function.
Keywords: Collagen type III; Fibrosis; Osteopontin; SVVYGLR peptide.
Similar articles
-
Osteopontin-derived synthetic peptide SVVYGLR upregulates functional regeneration of oral and maxillofacial soft-tissue injury.Jpn Dent Sci Rev. 2021 Nov;57:174-181. doi: 10.1016/j.jdsr.2021.09.002. Epub 2021 Sep 28. Jpn Dent Sci Rev. 2021. PMID: 34630775 Free PMC article. Review.
-
Overexpression of collagen type III in injured myocardium prevents cardiac systolic dysfunction by changing the balance of collagen distribution.J Thorac Cardiovasc Surg. 2018 Jul;156(1):217-226.e3. doi: 10.1016/j.jtcvs.2018.01.097. Epub 2018 Feb 21. J Thorac Cardiovasc Surg. 2018. PMID: 29551535
-
Improvement of cardiac function after implanting the osteopontin-derived peptide SVVYGLR in a hamster model of dilated cardiomyopathy.Interact Cardiovasc Thorac Surg. 2015 Oct;21(4):506-14. doi: 10.1093/icvts/ivv197. Epub 2015 Jul 17. Interact Cardiovasc Thorac Surg. 2015. PMID: 26188018
-
Thrombin-cleaved fragments of osteopontin are overexpressed in malignant glial tumors and provide a molecular niche with survival advantage.J Biol Chem. 2013 Feb 1;288(5):3097-111. doi: 10.1074/jbc.M112.362954. Epub 2012 Nov 30. J Biol Chem. 2013. PMID: 23204518 Free PMC article.
-
Osteopontin: A Promising Therapeutic Target in Cardiac Fibrosis.Cells. 2019 Dec 3;8(12):1558. doi: 10.3390/cells8121558. Cells. 2019. PMID: 31816901 Free PMC article. Review.
Cited by
-
Sustained and intermittent hypoxia differentially modulate primary monocyte immunothrombotic responses to IL-1β stimulation.Front Immunol. 2023 Sep 11;14:1240597. doi: 10.3389/fimmu.2023.1240597. eCollection 2023. Front Immunol. 2023. PMID: 37753073 Free PMC article.
-
Osteopontin-derived synthetic peptide SVVYGLR upregulates functional regeneration of oral and maxillofacial soft-tissue injury.Jpn Dent Sci Rev. 2021 Nov;57:174-181. doi: 10.1016/j.jdsr.2021.09.002. Epub 2021 Sep 28. Jpn Dent Sci Rev. 2021. PMID: 34630775 Free PMC article. Review.
-
Osteopontin N-Terminal Function in an Abdominal Aortic Aneurysm From Apolipoprotein E-Deficient Mice.Front Cell Dev Biol. 2021 Aug 12;9:681790. doi: 10.3389/fcell.2021.681790. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 34458254 Free PMC article.
-
The immune duality of osteopontin and its therapeutic implications for kidney transplantation.Front Immunol. 2025 Feb 28;16:1520777. doi: 10.3389/fimmu.2025.1520777. eCollection 2025. Front Immunol. 2025. PMID: 40093009 Free PMC article. Review.
-
Osteopontin Peptide Icosamer Containing RGD and SLAYGLR Motifs Enhances the Motility and Phagocytic Activity of Microglia.Exp Neurobiol. 2017 Dec;26(6):339-349. doi: 10.5607/en.2017.26.6.339. Epub 2017 Dec 11. Exp Neurobiol. 2017. PMID: 29302201 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials